Advanced Human Imaging Limited Sponsored ADR AHI
1.50
0.00
0.00%
as of 14 Aug
- Market cap
- $13.2M
- P/E
- 0.0×
Follow AHI
Growth Flags
show if company had growth for consecutive years
| Dec '23 | Jun '23 | Dec '22 | Jun '22 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 |
+6 more quarters Free account |
P/S ratio |
— | 60.75 | 33.06 | 27.30 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (7.08) | (4.96) | (2.28) | |
P/B ratio |
— | 25.71 | 3.43 | 2.62 | |
Price to Tangible BV |
— | 0.00 | 13.13 | 2.96 | |
EV/Sales |
— | 60.32 | 35.26 | 21.43 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | (1.99) | (0.91) | (0.87) | |
EV/FCF |
— | (1.97) | (0.91) | (0.86) | |
Quick Ratio |
0.10 | 0.40 | 0.56 | 2.96 | |
Current Ratio |
0.20 | 0.54 | 0.90 | 3.40 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
50.43% | 19.51% | 17.90% | 10.41% | |
Debt/Equity |
(1.14) | 0.86 | 0.32 | 0.13 | |
Asset Turnover |
0.00 | 0.10 | 0.07 | 0.11 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | (0.18) | 0.00 | (0.24) | |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | 2,476.05% | 1,497.99% | 14,836.51% | |
Intangible Assets out of Total Assets |
0.59 | 0.48 | 0.41 | 0.09 | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
— | (0.07) | (0.07) | 0.22 | |
Graham Number |
— | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
— | (3.84%) | (10.01%) | (8.54%) | |
Free Cash Flow Yield |
— | (50.37%) | (117.67%) | (91.39%) | |
Revenue per Share |
— | 0.02 | 0.03 | 0.01 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(3.13) | (5.01) | (2.88) | (7.22) | |
Working Capital |
(4.31) | (1.87) | (0.27) | 3.56 | |
Capital Expenditures |
0.00 | (0.05) | 0.00 | (0.06) | |
Net Current Asset Value |
(5.61) | (2.44) | (1.02) | 3.52 | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
— | (3,057.20%) | (1,091.45%) | (14,693.71%) | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.16 | 0.23 | 0.58 | 0.17 | |
Average Payables |
1.94 | 1.44 | 0.67 | 0.57 | |
Average Assets |
8.38 | 5.71 | 6.47 | 5.35 | |
Average Common Equity |
3.72 | 1.67 | 3.62 | 3.33 |
Columns are period end dates